Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 5/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8703869 | 0.86 | SMPD1 (0.52) | SMPD1LMNAGABRA5 | |
| SCHEMBL3114205 | 0.86 | SMPD1 (0.52) | SMPD1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27224857 | 0.86 | SMPD1 (0.55) | SMPD1TSHRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8708054 | 0.85 | MAOB (0.51) | SMPD1ALDH1A1TSHRNPC1RAB9A | |
| SCHEMBL8703430 | 0.85 | MRGPRX4 (0.54) | SMPD1GABRA5MEN1KMT2A | |
| SCHEMBL8707363 | 0.85 | SMPD1 (0.51) | SMPD1LMNAHPGDGABRA5ALOX5 | |
| SCHEMBL10521252 | 0.85 | SMPD1 (0.60) | SMPD1GABRA5ALDH1A1SMN1; SMN2PTGES | |
| SCHEMBL630848 | 0.85 | SMPD1 (0.63) | SMPD1NPC1RAB9APTGESALOX5 | |
| SCHEMBL18896166 | 0.85 | SMPD1 (0.64) | SMPD1HPGDGABRA5ALDH1A1SMN1; SMN2 | |
| SCHEMBL15004563 | 0.84 | SMPD1 (0.67) | SMPD1LMNAHPGDGABRA5SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12275716-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | ECCOGENE INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | ECCOGENE INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240109917-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2024-04-04 | — | — | US | disclosed |
| CN-117551089-A | Estrogen receptor proteolytic modulators and related methods of use | 阿尔维纳斯运营股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-4267585-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | Actelion Pharmaceuticals Ltd (CH) | 2023-11-01 | — | — | EP | disclosed |
| CN-110612297-B | Estrogen receptor proteolytic modulators and related methods of use | 阿尔维纳斯运营股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-2655362-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | Abbvie Inc. (US) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012087833-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-2419413-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-8017638-B2 | Isoxazole derivative and isothiazole derivative having inhibitory activity on 11β-hydroxysteroid dehydrogenase type 1 | SHIONOGI & CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| WO-2010119992-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-21 | — | — | WO | disclosed |
| US-20100197662-A1 | HETEROCYCLIC COMPOUND HAVING TYPE I 11 BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-7763735-B2 | modular synthesis of tetracycline analogs through a chiral enone intermediate; efficiency | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-07-27 | — | — | US | disclosed |
| US-20090131491-A1 | ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11(beta)-HYDROXYSTEROID DEHYDROGENASE TYPE I | SHIONOGI & CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090093640-A1 | modular synthesis of tetracycline analogs through a chiral enone intermediate; efficiency | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | RBP4, RBP1, FABP4 | SMPD1 1633/4885LMNA 1842/4885HPGD 3972/4885 |
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | GLP1R, GIPR, SLC5A1 | SMPD1 1961/4885LMNA 2596/4885HPGD 2251/4885 |
| US-20100197662-A1 | HETEROCYCLIC COMPOUND HAVING TYPE I 11 BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | HSD11B1, HSD3B1, HSD11B2 | SMPD1 543/4885LMNA 2799/4885HPGD 154/4885 |
| US-20090093640-A1 | modular synthesis of tetracycline analogs through a chiral enone intermediate; efficiency | TECR, TSN, TARS2 | SMPD1 4683/4885LMNA 1906/4885HPGD 2121/4885 |
| US-20090131491-A1 | ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11(beta)-HYDROXYSTEROID DEHYDROGENASE TYPE I | HSD3B1, NR5A1, HSD11B1 | SMPD1 1746/4885LMNA 3345/4885HPGD 395/4885 |
| US-12275716-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | SMPD1 2303/4885LMNA 2487/4885HPGD 3052/4885 |
| US-20240109917-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | PDGFRA, PDGFRB, ABL1 | SMPD1 1006/4885LMNA 3351/4885HPGD 2138/4885 |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | CRBN, ADRM1, MDM2 | SMPD1 3186/4885LMNA 675/4885HPGD 4417/4885 |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | SMPD1 3199/4885LMNA 1887/4885HPGD 4053/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | SMPD1 4042/4885LMNA 1254/4885HPGD 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.